Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis

Summary

This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.

Timeline

Start

2020-11-12

Primary completion

2021-10-21

Completion

2021-10-21

Outcome

Missed primary endpoint

registry analysis (superiority test); LY3556050 600 mg vs Placebo; Posterior Mean Difference 0.09 (95% CI -0.51 to 0.67) NCT04627038 ↗

Drugs

Indications